首页> 外文期刊>JGH OPEN >Gastrointestinal manifestation as clinical predictor of severe COVID‐19: A retrospective experience and literature review of COVID‐19 in Association of Southeast Asian Nations (ASEAN)
【24h】

Gastrointestinal manifestation as clinical predictor of severe COVID‐19: A retrospective experience and literature review of COVID‐19 in Association of Southeast Asian Nations (ASEAN)

机译:胃肠表现形式作为严重Covid-19的临床预测因子:东南亚国家科技署科技赛综合述评及其文献综述(东盟)

获取原文
           

摘要

Background and Aim Coronavirus disease 19 (COVID‐19) has caused over 200?000 deaths worldwide. Thailand announced the first confirmed case outside mainland China in January 2020. The disease also spread widely across Association of Southeast Asian Nations (ASEAN). Gastrointestinal manifestations could be presenting symptoms of COVID‐19. This study aimed to determine the prevalence of gastrointestinal manifestations of COVID‐19 patients in Thailand and review important aspects of this disease in ASEAN. Methods Thai patients diagnosed with COVID‐19 at Thammasat University Hospital, Thailand, were evaluated between 1 January 2020 and 30 April 2020. Patients' data, clinical presentation, exposure risk, past medical history, laboratory results, and treatment outcomes were extensively reviewed. Results A total of 352 COVID‐19 tests were performed, and 40 patients with positive tests were studied. The mean age was 30.5?years, and 55% were female. Most (82.5%) had no underlying diseases. Comorbidities were associated with severe COVID‐19 (odds ratio [OR] 29.93; 95% confidence interval [CI] 2.31–388.40, P = 0.009). Gastrointestinal symptoms were present in 12 patients (30%). The most common presenting symptoms were anorexia (17.5%) and diarrhea (15%). Gastrointestinal symptoms developed before (9.1%), concurrent with (63.6%), and after (27.3%) respiratory symptoms. Diarrhea was significantly associated with severe COVID‐19 (OR 38.52; 95% CI 3.11–476.70, P = 0.004). Twenty‐four patients (60%) received antiviral drugs; 40% had only supportive care. Only one patient required intensive care. No patient died. Conclusions Gastrointestinal manifestations in COVID‐19 patients are common symptoms and can occur anytime during the disease course. Patients presenting with only gastrointestinal symptoms should raise clinical suspicion for COVID‐19 in areas with high disease incidence. Clinically severe COVID‐19 was associated with comorbidities and diarrhea.
机译:背景和AIM冠状病毒疾病19(Covid-19)在全球范围内造成200 00 000多名死亡。泰国于2020年1月宣布了中国大陆以外的第一个确认案件。该疾病还广泛地遍布东南亚国国家(东盟)的协会。胃肠道表现可能是呈现Covid-19的症状。本研究旨在确定泰国Covid-19患者胃肠道表现的患病率,并在东盟审查这种疾病的重要方面。方法对泰国泰国泰国泰国Covid-19诊断的泰国患者在2020年1月1日至4月30日至4月30日评估。患者的数据,临床介绍,暴露风险,过去的病史,实验室结果和治疗结果得到了广泛的审查。结果总共进行了352个Covid-19测试,研究了40例阳性测试患者。平均年龄为30.5?年龄,55%是女性。大多数(82.5%)没有潜在的疾病。合并症与严重的Covid-19(差距[或] 29.93; 95%置信区间[C 1] 2.31-388.40,P = 0.009)相关。 12名患者中存在胃肠道症状(30%)。最常见的呈现症状是厌食症(17.5%)和腹泻(15%)。胃肠道症状在之前(9.1%),同时同时(63.6%),后(27.3%)呼吸系统症状。腹泻与严重的Covid-19(或38.52; 95%CI 3.11-476.70,P = 0.004)显着相关。二十四名患者(60%)接受抗病毒药物; 40%只有支持性护理。只有一名患者需要密集护理。没有病人死亡。结论Covid-19患者中的胃肠道表现是常见的症状,并且可以在疾病过程中随时发生。患者只有胃肠道症状,应在高疾病发病率的区域提高Covid-19的临床怀疑。临床上严重的Covid-19与合并症和腹泻有关。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号